Iterion Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer and other serious diseases. The company's lead product, Tegavivint, is a potent and selective inhibitor of transducin beta-like protein 1 (TBL1), a key component of the Wnt beta-catenin signaling pathway. Dysregulation of this pathway is associated with increased nuclear activity that activates genes linked to cancer and fibrosis. Iterion Therapeutics is currently enrolling patients in a Phase 1 clinical study of Tegavivint for the treatment of desmoid tumors, a rare and aggressive type of tumor. The company operates in the biopharmaceutical market, targeting oncologists and healthcare providers who treat cancer and fibrotic diseases. Iterion's business model involves the development and commercialization of its proprietary therapies, generating revenue through product sales, partnerships, and licensing agreements. The company aims to bring innovative treatments to patients with high unmet medical needs.

Keywords: biopharmaceutical, cancer therapy, fibrosis, Wnt pathway, TBL1 inhibitor, Tegavivint, clinical-stage, desmoid tumors, oncology, novel therapies.